Table 1 Patient characteristics (ITT population)
Baseline characteristics | Vandetanib 100 mg (n= 10) | Vandetanib 300 mg (n= 12) |
|---|---|---|
Median age, years (range) | 62.5 (38--77) | 61 (41--73) |
Male (%) | 6 (60) | 5 (42) |
Female (%) | 4 (40) | 7 (58) |
Race | ||
Caucasian (%) | 10 (100) | 12 (100) |
WHO performance status (%) | ||
0 1 | 6 (60) 4 (40) | 8 (67) 4 (33) |
Previous chemotherapy regimens (%) | ||
Any | 10 (100) | 12 (100) |
1 | 1 (10) | 4 (33) |
2 | 3 (30) | 2 (17) |
3 or more | 6 (60) | 6 (50) |
Prior cetuximab therapy (%) | 7 (70) | 7 (58) |
Prior bevacizumab therapy (%) | 5 (50) | 4 (33) |